You just read:

FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma

News provided by

Amgen

Sep 18, 2015, 04:01 ET